Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer-Reference-Cited by-同舟云学术

Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer

Published:2022-09-10 Issue:11 Volume:30 Page:9329-9340
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

McCall Maura K.^ORCID,Sereika Susan M.,Snader Stephanie,Lavanchy Alexa,Rosenzweig Margaret Q.,Conley Yvette P.,Beumer Jan H.,Bender Catherine M.

Funder

National Cancer Institute

Oncology Nursing Society Foundation

Rockefeller University

American Cancer Society

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-022-07326-6.pdf

Reference46 articles.

1. Howlader N, et al. SEER Cancer Statistics Review 1975–2016. 2019 April 2019 [cited 2019 September 24]; based on November 2018 SEER data submission]. Available from: https://seer.cancer.gov/csr/1975_2016/.

2. Howlader N et al (2018) Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 27(6):619–626

3. Miller KD et al (2019) (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin 69(5):363–385

4. Early Breast Cancer Trialists’ Collaborative G (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352

5. Desta Z et al (2009) Antiestrogen pathway (aromatase inhibitor). Pharmacogenet Genomics 19(7):554–555

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuropsychological assessment, intervention, and best practices for women with non-Central nervous system cancer: A scoping review of current standards;The Clinical Neuropsychologist;2024-04-20